Why Is Replimune Stock (REPL) Up 105% Today?
I'm PortAI, I can summarize articles.
Replimune's stock surged 105% after the FDA accepted its resubmission of the BLA for RP1, with a PDUFA date set for April 10, 2026. The company addressed FDA feedback and believes it has provided a complete response. CEO Sushil Patel expressed optimism about expediting the review for advanced melanoma treatment. Despite today's gains, Replimune's stock has fallen 62.84% year-to-date and 60.35% over the past year, with heavy trading volume of 51 million shares compared to a three-month average of 4.13 million.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments